Prescribing information can be found at the bottom of the page
Reduce the long-term risk of CV events with Invokana
- CANVAS showed a 14% relative reduction in risk for MACE among a mix of both primary and secondary prevention patients.
HR: 0.86 (95% Cl, 0.75-0.97)1 ARR: 4.6 fewer events per 1000 patient-years.
All-cause mortality was the first secondary endpoint in the pre-specified hypothesis testing sequence.
Because analysis of this endpoint failed to show superiority for Invokana, hypothesis testing could not be carried out for the other secondary endpoints.
Simplified statistics (hazard ratios and nominal 95% CIs) are shown for these additional endpoints, but these are not statistically significant.
- Neal B, et al. N Engl J Med. 2017;377(7):644-57